Contact us Find us Register
Back to previous section

Cambridge Cognition secures two contracts with 'major pharmaceutical company'.

Software firm Cambridge Cognition revealed on Thursday that it has been selected by "a major pharmaceutical company" to provide digital cognitive and voice assessments for two Phase 3 clinical trials in adolescents with Major Depressive Disorder.

  • Cambridge Cognition Holdings
  • 03 April 2025 10:53:22
Cambridge Cognition

Source: Sharecast

Cambridge Cognition said both contracts were set to commence in the current trading year, with the first running until 2027 and the second through to 2029.

The AIM-listed firm said the total value of the combined contracts was estimated at approximately £1.2m.

Chief operating officer Rob Baker said: "This strategically important contract win highlights the value of our integrated speech and cognitive platform that not only delivers robust and reliable results for the pharmaceutical company but also reduces trial costs and patient burden.

"As a result, we see significant future demand for our unique platform, and we remain confident in our ambitions to significantly grow sales in the high-impact, late-stage CNS trials market over the coming years."

As of 1050 BST, Cambridge Cognition shares were up 0.69% at 36.25p.

Reporting by Iain Gilbert at Sharecast.com

N/A

ISIN: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.